MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
3.185
-0.025 (-0.78%)
May 14, 2026, 12:25 PM EDT - Market open
MannKind Revenue
MannKind had revenue of $90.17M in the quarter ending March 31, 2026, with 15.08% growth. This brings the company's revenue in the last twelve months to $360.78M, up 21.23% year-over-year. In the year 2025, MannKind had annual revenue of $348.97M with 22.23% growth.
Revenue (ttm)
$360.78M
Revenue Growth
+21.23%
P/S Ratio
2.74
Revenue / Employee
$609,431
Employees
592
Market Cap
984.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 348.97M | 63.46M | 22.23% |
| Dec 31, 2024 | 285.50M | 86.54M | 43.50% |
| Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
| Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
| Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
| Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
| Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
| Dec 31, 2018 | 27.86M | 16.11M | 137.20% |
| Dec 31, 2017 | 11.75M | -163.01M | -93.28% |
| Dec 31, 2016 | 174.76M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 204.89M |
| Xencor | 97.36M |
| Septerna | 72.26M |
| Lexicon Pharmaceuticals | 69.64M |
| Aktis Oncology | 8.28M |
MNKD News
- 7 days ago - MannKind price target lowered to $7 from $8 at Mizuho - TheFly
- 7 days ago - MannKind price target raised to $10 from $8 at H.C. Wainwright - TheFly
- 7 days ago - MannKind price target raised to $10 from $8 at Wells Fargo - TheFly
- 7 days ago - MannKind reports Q1 EPS (2c), consensus 1c - TheFly
- 7 days ago - MannKind Earnings Call Transcript: Q1 2026 - Transcripts
- 7 days ago - MannKind Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases - GlobeNewsWire
- 14 days ago - MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 - GlobeNewsWire